NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it is moving forward with the development of a novel diagnostic to help identify which cancer patients are most likely to benefit from treatment with immune checkpoint inhibitors under an SBIR contract awarded by the National Institutes of Health late last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.